Legend Biotech Corporation has announced new long-term clinical and translational data for its CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) therapy from the CARTITUDE-1 and CARTITUDE-4 studies in patients with relapsed or refractory multiple myeloma. In triple-class-exposed patients who had received three prior lines of therapy, a median progression-free survival of 50.4 months was observed following a single infusion of CARVYKTI®. Additionally, 80% of patients with standard-risk cytogenetics in the CARTITUDE-4 study remained progression-free and off treatment at 30 months after a single infusion. The results were presented at the American Society of Hematology $(ASH)$ 2025 annual meeting. Legend Biotech also presented first-in-human clinical data for its allogeneic CAR-T candidate LUCAR-G39D in adults with relapsed or refractory B-cell non-Hodgkin lymphoma. The study demonstrated a manageable safety profile and encouraging antitumor activity, with an overall response rate of 75% and a complete response rate of 37.5% among treated patients. No dose-limiting toxicities, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease were reported. These results were also presented at ASH 2025.